Bevacizumab Treatment to Progression After Chemotherapy: Outcomes from a U.S. Community Practice Network

Bevacizumab significantly extends progression-free survival (PFS) and overall survival (OS) times when combined with initial chemotherapy and continued as monotherapy until disease progression or unacceptable toxicity in patients with nonsquamous non-small cell lung cancer (NSCLC). In clinical pract...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Nadler, Eric, Yu, Elaine, Ravelo, Arliene, Sing, Amy, Forsyth, Michael, Gruschkus, Stephen
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AlphaMed Press 2011
Gaiak:
Lung Cancer
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228113/
https://ncbi.nlm.nih.gov/pubmed/21441299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0287
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak